From: The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis
Subgroups | Studies/N | Patients/N | Pooled HR (95% CI, P) | Heterogeneity (P, I², Model) |
---|---|---|---|---|
mGPS: high vs. low | ||||
Overall | 12 | 2009 | 1.504, (1.197–1.891), < 0.0001 | 0.003, 61.7%, random |
Region | ||||
East | 9 | 1668 | 1.597, (1.240–2.056), < 0.0001 | 0.071, 44.7%, fixed |
West | 3 | 341 | 1.342, (0.797–2.258), 0.268 | 0.002, 83.8%, random |
Therapy | ||||
Chemotherapy | 7 | 932 | 1.455, (1.048–2.020), 0.025 | 0.001, 74.2%, random |
Pancreatectomy | 5 | 1077 | 1.638, (1.247–2.150), < 0.0001 | 0.345, 10.7%, fixed |
mGPS: 1 vs. 0 | ||||
Overall | 8 | 4503 | 1.683, (1.247–2.269), 0.001 | < 0.0001, 86.6%, random |
Region | ||||
East | 7 | 4401 | 1.711, (1.248–2.347), 0.001 | < 0.0001, 88.5%, random |
West | 1 | 102 | 1.346, (0.585–3.098), 0.485 | – |
Therapy | ||||
Chemotherapy | 6 | 2968 | 1.780, (1.297–2.443), < 0.0001 | < 0.0001, 83.9%, random |
Pancreatectomy | 2 | 1535 | 1.521, (0.602–3.838), 0.375 | 0.001, 91.4%, random |
mGPS: 2 vs. 0 | ||||
Overall | 8 | 4503 | 1.899, (1.356–2.660), < 0.0001 | < 0.0001, 80.4%, random |
Region | ||||
East | 7 | 4401 | 1.833, (1.285–2.615), 0.001 | < 0.0001, 82.3%, random |
West | 1 | 102 | 2.712, (1.252–5.875), 0.011 | – |
Therapy | ||||
Chemotherapy | 6 | 2968 | 1.872, (1.174–2.984), 0.008 | < 0.0001, 81.5%, random |
Pancreatectomy | 2 | 1535 | 2.011, (0.941–4.297), 0.078 | 0.003, 88.3%, rrandom |